| Literature DB >> 26649172 |
Siddhartha Saha1, Bharti Gaur Pandey2, Avinash Choudekar3, Anand Krishnan4, Susan I Gerber5, Sanjay K Rai4, Pratibha Singh6, Mandeep Chadha7, Renu B Lal1, Shobha Broor8.
Abstract
BACKGROUND: The burden estimation studies for respiratory syncytial virus (RSV) have been based on varied case definitions, including case-definitions designed for influenza surveillance systems. We used all medical admissions among children aged 0-59 months to study the effect of case definitions on estimation of RSV-associated hospitalizations rates.Entities:
Mesh:
Year: 2015 PMID: 26649172 PMCID: PMC4652925 DOI: 10.7189/jogh.05.020419
Source DB: PubMed Journal: J Glob Health ISSN: 2047-2978 Impact factor: 4.413
Characteristics of children <5 years of age enrolled for all cause hospitalization in Ballabgarh, Haryana, India from July 2009 – December 2012
| Characteristics (n, %) | Total (n = 505) | RSV+ (n = 82) | RSV– (n = 423) | |
|---|---|---|---|---|
| 0–5 | 114 (22.6) | 35 (42.7) | 79 (18.7) | <0.001 |
| 6–11 | 146 (28.9) | 16 (19.5) | 130 (30.7) | |
| 12–23 | 142 (28.1) | 22 (26.8) | 120 (28.4) | |
| 24–35 | 43 (8.5) | 4 (4.9) | 39 (9.2) | |
| 36–59 | 60 (11.9) | 5 (6.1) | 55 (13) | |
| Female | 143 (28.3) | 24 (29.3) | 119 (28.1) | 0.834 |
| Male | 362 (71.7) | 58 (70.7) | 304 (71.9) | |
| 0–2 days | 127/468 (27.1) | 16/79 (20.2) | 111/389 (28.5) | 0.497 |
| 3–4 days | 135/468 (28.8) | 26/79 (32.9) | 109/389 (28.0) | |
| 5–7 days | 116/468 (24.8) | 21/79 (26.6) | 95/389 (24.4) | |
| 8–10 days | 39/468 (8.3) | 9/79 (11.4) | 30/389 (7.7) | |
| ≥11 days | 51/468 (10.9) | 7/79 (8.9) | 44/389 (11.3) | |
*Data on 37 cases, including 3 RSV–positive cases, were missing.
Age–specific clinical signs and symptoms significantly associated with laboratory–confirmed respiratory syncytial virus infection among hospitalized patients <5 y of age, in Ballabgarh, India, July 2009 – December 2012; (n = 505)*
| 0–5 months | 6–23 months | 24–59 months | 0–59 months | |||||
|---|---|---|---|---|---|---|---|---|
| Fever | 27 (77.1) | 0.6 (0.2–1.6) | 32 (84.2) | 0.8 (0.3–2.2) | 9 (100.0) | – | 68 (82.9) | 0.8 (0.4–1.5) |
| Cough | 32 (91.4) | 4.4 (1.2–15.7) | 32 (84.2) | 6.5 (2.6–16.0) | 6 (66.7) | 1.6 (0.4–6.8) | 70 (85.4) | 5.3 (2.8–10.1) |
| Breathing difficulty | 20 (57.1) | 3.5 (1.5–7.9) | 15 (39.5) | 3.3 (1.6–6.9) | 2 (22.2) | 1.5 (0.3–8) | 37 (45.1) | 1.8 (1.1–2.7) |
| Nasal discharge | 13 (37.1) | 1.4 (0.6–3.1) | 20 (52.6) | 2.3 (1.1–4.5) | 4 (44.4) | 2 (0.5–8) | 37 (45.1) | 1.8 (1.1–2.9) |
| Sore throat (>2years) | 0 (0) | – | 0 (0) | – | 2 (22.2) | 1.5 (0.3–8) | 2 (16.7) | 1.4 (0.3–7.1) |
| Ear discharge | 1 (2.9) | 1.1 (0.1–12.9) | 4 (10.5) | 2.3 (0.7–7.6) | 0 (0) | – | 5 (6.1) | 1 (0.4–2.7) |
| Fast breathing | 18 (51.4) | 2.9 (1.3–6.7) | 18 (47.4) | 6.1 (2.9–12.8) | 3 (33.3) | 3.8 (0.8–17.3) | 39 (47.6) | 3.9 (2.4–6.3) |
| Lethargy | 9 (25.7) | 1.5 (0.6–3.9) | 3 (7.9) | 0.3 (0.1–0.9) | 3 (33.3) | 1.2 (0.3–5) | 15 (18.3) | 0.7 (0.4–1.2) |
| Refusal to feed | 15 (42.9) | 1 (0.5–2.3) | 10 (26.3) | 0.6 (0.3–1.3) | 3 (33.3) | 0.8 (0.2–3.3) | 28 (34.2) | 0.8 (0.5–1.3) |
| Seizure | 2 (5.7) | 0.9 (0.2–4.9) | 0 (0) | – | 2 (22.2) | 6.4 (1–41.4) | 4 (4.9) | 1.6 (0.5–4.7) |
| Unconsciousness | 2 (5.7) | 0 (0–0) | 0 (0) | – | 0 (0) | – | 2 (2.4) | 1.5 (0.2–11) |
| Vomiting | 10 (28.6) | 0.4 (0.2–0.9) | 22 (57.9) | 0.4 (0.2–0.8) | 4 (44.4) | 0.5 (0.1–2) | 36 (43.9) | 0.4 (0.2–0.6) |
| Diarrhea | 13 (37.1) | 0.5 (0.2–1.2) | 16 (42.1) | 0.2 (0.1–0.4) | 1 (11.1) | 0.2 (0–1.7) | 30 (36.6) | 0.3 (0.2–0.5) |
| Rash | 1 (2.9) | 2.3 (0.1–37.8) | 0 (0) | – | 0 (0) | – | 1 (1.2) | 0.3 (0–2.6) |
| Jaundice | 1 (2.9) | 1.1 (0.1–12.9) | 0 (0) | – | 0 (0) | – | 1 (1.2) | 0.7 (0.1–4.2) |
| Fever | 1 (2.9) | 0.2 (0–1.3) | 10 (26.3) | 1.8 (0.8–4) | 6 (66.7) | 5 (1.2–21.3) | 17 (20.7) | 1.1 (0.6–2) |
| Stridor | 4 (11.4) | 2.4 (0.6–10.3) | 5 (13.2) | 9.3 (2.4–36.5) | 0 (0) | 0 (0–0) | 9 (11) | 5.7 (2.2–14.8) |
| Nasal flaring | 5 (14.3) | 2.4 (0.6–8.9) | 4 (10.5) | 9.7 (2.1–45.2) | 0 (0) | 0 (0–0) | 9 (11) | 5.1 (2–12.9) |
| Chest in–drawing | 13 (37.1) | 5.1 (1.2–13.9) | 6 (15.8) | 3.7 (1.3–10.6) | 0 (0) | 0 (0–0) | 19 (23.2) | 5.7 (2.9–11.3) |
| Grunting | 5 (14.3) | 3 (0.8–12.1) | 4 (10.5) | 7.2 (1.7–30.3) | 0 (0) | 0 (0–0) | 9 (11) | 5.6 (2.2–14.7) |
| Accessory muscle use | 5 (14.3) | 4.2 (0.9–18.8) | 1 (2.6) | 0.8 (0.1–6.7) | 0 (0) | 0 (0–0) | 6 (7.3) | 2.5 (0.9–6.8) |
| Crepitation | 21 (60) | 2.9 (1.3–6.6) | 17 (44.7) | 5.0 (2.4–10.3) | 4 (44.4) | 5.5 (1.3–23.2) | 42 (51.2) | 5 (3–8.2) |
| Wheeze | 24 (68.6) | 5 (2.1–11.8) | 10 (26.3) | 2.8 (1.2–6.4) | 2 (22.2) | 2.2 (0.4–11.7) | 36 (43.9) | 4.5 (2.7–7.5) |
| Tachypnoea | 25 (71.0) | 1.4 (0.6–3.3) | 16 (42.1) | 1.9 (0.9–3.8) | 1 (11.1) | 0.6 (0.1–4.8) | 42 (51.2) | 2.2 (1.4–3.5) |
| Hypoxia* | 8 (22.9) | 1.5 (0.6–4) | 8 (22.9) | 2.6 (1.0–6.6) | 1 (11.1) | 2.8 (0.3–28.3) | 17 (20.7) | 2.5 (1.3–4.8) |
OR – odds ratio, CI – confidence interval
*Defined as oxygen saturation <90% on room air or <95% on oxygen therapy.
Clinical predictors of respiratory syncytial virus associated hospitalization among children aged <5 y by stepwise backward logistic regression adjusted for age–groups*
| Symptoms and signs | Odds ratio (95% CI) | |
|---|---|---|
| Cough | 1.85 (1.13–0.46) | 0.013 |
| History of fever | 0.4 (0.23–0.11) | 0.001 |
| History of fast breathing | 3.44 (2.26–0.73) | <0.001 |
| Diarrhea | 0.62 (0.41–0.12) | 0.021 |
| Inability/refusal to feed | 0.57 (0.39–0.1) | 0.004 |
| Unconsciousness | 0.07 (0.01–0.07) | 0.005 |
| Nasal flaring | 3.13 (1.41–1.27) | 0.005 |
| Stridor | 2.73 (1.22–1.12) | 0.014 |
| Accessory muscle use | 0.22 (0.08–0.11) | 0.003 |
| Crepitation | 2.79 (1.81–0.61) | <0.001 |
| Hypoxia | 2.71 (1.58–0.74) | <0.001 |
CI – confidence interval
*Age groups: 0–5 months, 6–11 months, 12–23 months and 24–59 months.
Figure 1Receiver operator characteristic (ROC) chart for screening definitions for respiratory syncytial virus associated hospitalization with 1–specificity on x-axis and sensitivity on y-axis. Each dot represents the sensitivity and 1–specificity of the case definition for detection of RSV–associated hospitalization. See for case definitions details of each syndrome.
Figure 2Age–specific incidence rates using all–cause hospitalization for respiratory syncytial virus (RSV) and influenza–associated hospitalization rates in north India (2009–2012). The age groups are on the x–axis and incidence rate of RSV–associated hospitalization per 1000 children denoted on the y–axis. Green and orange colored bars denote incidence rates of RSV and influenza associated hospitalizations respectively with error bars for 95% confidence intervals.
Effect of screening case definition on respiratory syncytial virus (RSV) associated annual hospitalization rates (2010–2012)*
| Population under surveillance | Under–2 years (N = 3956) | Under–5 years (N = 9740) | ||||||
|---|---|---|---|---|---|---|---|---|
| All Medical | 386 | 67 (17) | 7.4 | NA | 484 | 74 (15) | 3.2 | NA |
| ARI (WHO) | 239 | 60 (25) | 6.6 | –10% | 299 | 64 (21) | 2.8 | –14% |
| SARI (WHO) | 90 | 34 (38) | 3.8 | –49% | 107 | 35 (33) | 1.5 | –53% |
| SARI (Old) | 35 | 10 (29) | 1.1 | –85% | 41 | 11 (27) | 0.5 | –85% |
| ILI (WHO) | 37 | 10 (27) | 1.1 | –85% | 54 | 14 (26) | 0.6 | –81% |
| ILI (Old) | 106 | 26 (25) | 2.9 | –61% | 139 | 32 (23) | 1.4 | –57% |
ARI – acute respiratory illness, SARI – severe acute respiratory illness, ILI – influenza–like illness, WHO – World Health Organization
*For incidence rate calculations data for full calendar years were used. Data imputed for 6 weeks surveillance gap between 31 January 2012 and 13 March 2012.
†Per 1000 age–specific population.